Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Guillermo de Velasco

Hospital Universitario 12 de Octubre

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Collaborators (9)

Ulka Vaishampayan

University of Michigan

UNITED STATES

Aly-Khan A. Lalani

McMaster University

Frede Donskov

University of Southern Denmark

Kaïssa Ouali

Institut Gustave Roussy

Sophie Postel-Vinay

Institut Gustave Roussy

Elena López Camacho

Profesor Contratado Doctor

Universidad Francisco de Vitoria

Lillian L. Siu

University Health Network

Javier Gavira Díaz

Institut Català d'Oncologia

Felix Guerrero-Ramos

Head of the bladder and kidney cancer unit

Universidad CEU San Pablo

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Guillermo de Velasco

Research Interests

Make your next move.

Explore related searches

Articles (20)

Collaborators (9)

Ulka Vaishampayan

Aly-Khan A. Lalani

Frede Donskov

Kaïssa Ouali

Sophie Postel-Vinay

Elena López Camacho

Lillian L. Siu

Javier Gavira Díaz

Felix Guerrero-Ramos

Make your next move.

Guillermo de Velasco

Research Interests

Make your next move.

Explore related searches

Articles (20)

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma

Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium

Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)

The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trial

Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti-PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study

Belzutifan plus lenvatinib versus cabozantinib in post-PD-(L)1 renal cell carcinoma (RCC): Health-related quality-of-life (HRQoL) outcomes in the phase 3 LITESPARK-011 study

Clinical Outcomes of Targeted Therapies Following HIF-2 α Inhibition in Metastatic Renal Cell Carcinoma: A Real-World Analysis

DEVELOPMENT AND VALIDATION OF A PROGNOSTIC MODEL TO GUIDE THE OPTIMAL TIMING OF DOCETAXEL AFTER AN ANDROGEN RECEPTOR PATHWAY INHIBITOR IN MCRPC

FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers

Nivolumab and ipilimumab maintenance therapy for advanced or metastatic urothelial carcinoma: Final results from SOGUG-VEXILLUM trial

Re: Daniel S. Roberson, Vidit Sharma, Stephen A. Boorjian, et al. Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/ or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis. Eur Urol 2025;88:212-4

Real-world analysis of renal cell carcinoma with sarcomatoid differentiation treated with first-line immunotherapy combinations: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

SASAN-SPARING: A phase 2 trial of sasanlimab maintenance as bladder-sparing option after neoadjuvant chemotherapy in patients with muscle invasive bladder cancer.

Selective bladder-sparing trial with sasanlimab as maintenance treatment based on clinical response to neoadjuvant treatment in molecularly categorized muscle invasive bladder cancer patients: SASAN-SPARING trial.

Targeting metastatic bladder cancer when money is an issue

AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors

Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT)

A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR study.

Split-Dose Cisplatin Plus Atezolizumab for Patients With Urothelial Carcinoma Who Are Considered Ineligible for Full Doses of Cisplatin (SOGUG-AUREA)

A novel prognostic model to optimize the timing of docetaxel (Doc) following an androgen receptor pathway inhibitor (ARPi) in metastasic castration-resistant prostate cancer (mCRPC).

Collaborators (9)

Ulka Vaishampayan

Aly-Khan A. Lalani

Frede Donskov

Kaïssa Ouali

Sophie Postel-Vinay

Elena López Camacho

Lillian L. Siu

Javier Gavira Díaz

Felix Guerrero-Ramos

Make your next move.